Treatment of MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease)

Nomenclature Reminder

1. Foundational: Lifestyle Modification

• 3-5% weight loss: improves hepatic steatosis

• 7-10% weight loss: improves MASH histology

• 10% weight loss: improves fibrosis

• <10% of patients sustain effective weight loss at 1 year with lifestyle alone

• Avoid saturated fats, refined carbohydrates, sugar-sweetened beverages, excess fructose
• Mediterranean diet is preferred for long-term adherence, cardiovascular benefit, and cross-cultural adaptability
• Avoid UDCA and omega-3 fatty acids as MASH-specific treatments (insufficient evidence)
• Coffee (≥3 cups/day) is associated with reduced fibrosis and HCC risk in epidemiologic studies

• Moderate exercise ≥5×/week totaling ≥150 min/week, OR
• More intensive exercise ≥60 min/week
• Aerobic and resistance training are both beneficial; type should be individualized
• In advanced fibrosis/cirrhosis: exercise reduces portal hypertension, sarcopenia, and HCC risk

2. Pharmacologic Therapy

2a. FDA-Approved MASH-Specific Drugs (as of 2026)

• Dose: 80 mg (BMI <35) or 100 mg (BMI ≥35) orally once daily
• MAESTRO-NASH phase 3 trial: significant MASH resolution and ≥1-stage fibrosis improvement vs placebo
• Mechanism: mimics hepatic T3, reduces intrahepatic triglycerides and lipotoxicity
• Side effects: nausea, diarrhea (usually mild/transient); monitor for drug-drug interactions (strong CYP2C8 inhibitors)
• Also approved in India: Saroglitazar (PPARα/γ agonist)

• ESSENCE trial (phase 3, 72 weeks):
  • MASH resolution without fibrosis worsening: 62.9% vs 34.3% placebo (p<0.001)
  • ≥1-stage fibrosis improvement: 36.8% vs 22.4% placebo (p<0.001)
• Patient selection: MASH F2-F3 fibrosis identified by non-invasive tests (NITs):
  • VCTE: 8-15 kPa (borderline 15-20 kPa: individualized)
  • MRE: 3.1-4.4 kPa
  • ELF score: 9.2-10.5
• NOT approved for MASH cirrhosis (VCTE >20 kPa, MRE >5 kPa, ELF >11.3)
• Monitoring: GI side effects (nausea, diarrhea, constipation, vomiting) - mild/transient; watch for pancreatitis, gallbladder disease, AKI, thyroid C-cell tumors, lean mass loss
• Combination resmetirom + semaglutide: not yet studied

Key point per AASLD 2025-2026 guidance (Bansal et al., Hepatology 2026): Liver biopsy is no longer required for patient selection - NITs (VCTE, MRE, ELF) are sufficient.

2b. Metabolic Comorbidity-Directed Drugs (indirect MASLD benefit)

2c. Pipeline Drugs (Phase 2b/3 - not yet approved)

1. Pegozafermin (FGF21 analog) - SUCRA 91.75 for MASH resolution
2. Survodutide (GLP-1/glucagon dual agonist) - SUCRA 90.87
3. Tirzepatide (GLP-1/GIP dual agonist) - SUCRA 84.70
4. Efruxifermin (FGF21 analog)
5. Lanifibranor (pan-PPAR agonist)

3. Bariatric/Metabolic Surgery

• Indicated in eligible patients with obesity (BMI ≥35, or ≥30 with comorbidities) who have not achieved goals with lifestyle/pharmacotherapy
• Sleeve gastrectomy and Roux-en-Y gastric bypass produce sustained weight loss sufficient to resolve MASH in most patients
• Improves fibrosis; long-term data on HCC reduction are emerging
• Endoscopic sleeve gastroplasty is an emerging less invasive option

4. Treatment of Advanced MASLD / Complications

• Compensated cirrhosis: surveillance for HCC every 6 months (ultrasound ± AFP), varices screening
• Decompensated cirrhosis: management of ascites, hepatic encephalopathy, variceal bleeding (same approach as other end-stage liver disease)
• Liver transplantation: indicated for end-stage liver disease; MASLD/MASH-related HCC is now one of the leading transplant indications; recurrence of metabolic disease post-transplant requires ongoing management

5. Monitoring Treatment Response

• ALT reduction ≥17-20 U/L from baseline suggests MASH resolution
• VCTE (FibroScan) LSM reduction ≥30% suggests fibrosis improvement
• MRE LSM reduction ≥20%
• ELF reduction ≥0.5

Summary Algorithm

MASLD diagnosed
    ↓
All patients: Lifestyle modification (diet + exercise) + manage metabolic comorbidities
    ↓
F2-F3 MASH (by NITs)?
    ↓ YES
Pharmacotherapy:
  - Resmetirom (FDA/EMA approved, liver fibrosis-focused)
  - Semaglutide 2.4 mg/wk (FDA approved Aug 2025, strong MASH resolution data)
  - Pioglitazone or Vitamin E in select patients (T2DM/non-diabetic without cirrhosis)
    ↓
F4 / Cirrhosis?
  - Specialist referral, HCC surveillance, transplant evaluation

• EASL-EASD-EASO Clinical Practice Guidelines 2024 - J Hepatol
• AASLD Practice Guidance update (semaglutide), Nov 2025 - Hepatology 2026
• Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Ch. Treatment of MASLD
• Network meta-analysis of MASH pharmacotherapies, Souza et al. 2025 - Hepatology

Role of Vildagliptin in MASLD

What is Vildagliptin?

• Dose: 50 mg once or twice daily orally
• Approved indication: Type 2 diabetes mellitus (T2DM)

Proposed Mechanisms in MASLD

1. GLP-1 Enhancement

• Reduce hepatic lipogenesis
• Decrease oxidative stress
• Improve insulin sensitivity

2. Insulin Sensitization

• Upregulates the IRS-1/PI3K/Akt signaling pathway, restoring insulin receptor signal transduction
• Reduces hyperinsulinemia-driven hepatic de novo lipogenesis

3. Anti-inflammatory Effects (preclinical evidence)

• Inhibits TNF-α, NF-κB, JNK, and JAK/STAT pro-inflammatory pathways in hepatocytes
• Reduces infiltration of inflammatory cells in hepatic tissue

4. Antioxidant Effects

• Reduces oxidative stress markers in the liver

5. Antifibrotic Effects (preclinical)

• Downregulates the TGF-β1 pathway, which is the central driver of hepatic stellate cell activation and fibrosis

Clinical Evidence

RCT: Vildagliptin vs. Metformin in T2DM with Hepatic Steatosis (2024)

• Both vildagliptin (50 mg BD) and metformin (up to 2000 mg/day) significantly improved:
  • Fasting blood glucose, HbA1c
  • Body weight, BMI, waist circumference
  • Hepatic Steatosis Index (HSI)
  • Ultrasound-graded hepatic steatosis at 6 months
• No significant difference between vildagliptin and metformin in degree of steatosis improvement on ultrasound
• Metformin produced greater reductions in weight and BMI
• Total cholesterol and LDL were identified as the stronger predictors of hepatic steatosis

Observational Study: Gliptin therapy and hepatic/myocardial fat (2017)

Preclinical: Antifibrotic effects in NASH rats (2022)

• Vildagliptin (10 and 20 mg/kg) dose-dependently:
  • Reduced hepatic fat, inflammation (TNF-α, NF-κB, JNK/JAK-STAT)
  • Improved insulin sensitivity (IRS-1/PI3K/Akt upregulation)
  • Attenuated liver fibrosis via TGF-β1 pathway downregulation
• These are promising mechanistic data but require human validation

The Critical Verdict: DPP-4 Inhibitors as a Class in MASLD

"DPP-4 inhibitors had no significant effect on liver histology, liver fat content, liver enzymes, triglycerides, body weight, BMI, or waist circumference - except for lowering HbA1c."

• GLP-1 RAs: resolved MASH in 3.33× more patients (RR 3.33, 95% CI 2.38-4.66), reduced liver fat by 4.34%
• DPP-4 inhibitors: only improved HbA1c (WMD -0.62%), with no hepatic histological or functional benefit

Current Guideline Position

Summary

Clinical bottom line

Safety note: Rare cases of hepatic dysfunction, including hepatitis, have been reported with vildagliptin specifically; liver enzyme monitoring quarterly in the first year is recommended (Katzung's Basic & Clinical Pharmacology, 16th Ed.).